Bacil Pharma opened at ₹16.95, in line with its previous close of ₹16.95. In the last trading session on 12 Nov 2026, the stock traded between ₹16.11 and ₹16.99, with an average traded price of ₹16.53. It showed a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Bacil Pharma is now worth
₹ 23,407.00
Giving a profit of
₹ 13,407.00 (134.07%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.05 (-0.30%)
Day High
₹16.99
Day Low
₹16.11
Day Open
₹16.95
Prev Close
₹16.95
Volume
1,603
Value Traded
₹0.00 Cr
1W Return
-3.15%
1M Return
-31.77%
3M Return
10.53%
6M Return
-70.77%
1Y Return
-39.84%
Market Cap (₹ Cr.)
24
PE Ratio
15.70
PB Ratio
0.97
Dividend Yield
-
ROE
6.27%
ROCE
3.99%
Book Value (₹)
17.55
Face Value (₹)
10.00
EPS (TTM)
0.06
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-3.15%
6 Weeks
-
1 Month
-31.77%
3 Months
10.53%
9 Months
-57.22%
No data available.
Bacil Pharma subsidiary signs ₹35 crore R&D deal with Efdee Pharma
Bacil Pharma's subsidiary signed an R&D agreement with Efdee Pharma. The total estimated cost of the project is ₹35 crore. Scope includes development of pellets, granules, powders, tablets, and capsules. Agreement executed by Bacil Research and Development Private Limited.
8 days agoBacil Pharma Q2FY27 Results: Net loss of ₹0.98 lakh, other income ₹9.18 lakh
Net loss of ₹0.98 lakh in Q2FY27 versus ₹6.64 lakh profit in Q1FY27. Total revenue of ₹9.18 lakh in Q2FY27, derived entirely from other income. H1FY27 profit before tax dropped to ₹9.89 lakh from ₹91.20 lakh in H1FY26. Deferred tax expense of ₹4.23 lakh contributed to the quarterly net loss.
29 days agoBacil Pharma CS Dikshant Singh Panwar resigns effective Oct 8
Dikshant Singh Panwar resigned as Whole-Time Company Secretary of Bacil Pharma Ltd. Resignation effective from October 8, 2026, accepted by the company on the same day. Reason cited was increasing personal and professional commitments requiring dedicated attention. Company is initiating process to appoint a new Company Secretary and Compliance Officer.
1mo agoBacil Pharma AGM approves MD appointment and auditor change
All nine AGM resolutions passed with requisite majority as per scrutinizer report. Chaitali Kalpataru Shah elevated to Managing Director with 99.93% votes in favour. M/s Sarang Shivajirao Chavan & Associates appointed as new statutory auditors. Authorized share capital increase approved to facilitate future corporate actions.
1mo agoBacil Pharma sets Sept 23 AGM for ₹70 crore capital hike, MD appointment
Bacil Pharma schedules AGM for September 23, 2026, to approve ₹70 crore capital hike. Chaitali Kalpataru Shah proposed for elevation to Managing Director. FY26 net loss of ₹61.88 lakh reported despite PBT doubling to ₹99.02 lakh. Zero operational revenue; growth driven by other income and investment activities.
2mo agoBacil Pharma appoints Mahesh Singh, Anil Shiv Charan Singh to board
Bacil Pharma appoints Mahesh Singh as independent director. Anil Shiv Charan Singh joins as non-executive director. Appointments subject to shareholder approval. Board met on August 25, 2026 to approve changes.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,899.30 | +0.76% | ₹4,55,705.69 | 41.20 | +9.65% | |
| ₹11,495.00 | +0.09% | ₹3,05,156.13 | 90.40 | +76.30% | |
| ₹4,685.20 | -0.89% | ₹1,78,209.95 | 85.50 | +22.50% | |
| ₹2,427.00 | +1.13% | ₹1,31,133.78 | 97.10 | +145.34% | |
| ₹1,204.50 | -0.12% | ₹1,20,149.34 | 28.00 | +26.60% | |
| ₹1,388.30 | +0.12% | ₹1,15,878.66 | 42.00 | +12.91% | |
| ₹1,409.80 | +0.11% | ₹1,13,891.88 | 39.90 | -7.21% | |
| ₹2,663.30 | +0.94% | ₹1,10,006.30 | 48.10 | +17.33% | |
| ₹1,808.90 | +0.09% | ₹1,04,080.11 | 26.00 | +52.83% | |
| ₹2,019.10 | +0.20% | ₹92,331.42 | 17.60 | -0.73% | |
| ₹2,639.00 | -0.78% | ₹74,479.09 | 51.60 | +42.82% | |
| ₹5,194.00 | -2.04% | ₹62,102.06 | 30.50 | -9.94% |
An investment of ₹10,000 made 5 years ago in Bacil Pharma is now worth
₹ 23,407.00
Giving a profit of
₹ 13,407.00 (134.07%)
Note: Past profits do not guarantee future returns.
